NCT00618995View on ClinicalTrials.gov

A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Comparator: ER niacin (+) laropiprant

ER niacin 2 g/ laropiprant 40 mg daily for 7 days.

DRUG

Comparator: ER niacin

ER niacin 2 g daily for 7 days.

DRUG

Comparator: laropiprant

laropiprant 40 mg daily for 7 days.

DRUG

Comparator: placebo

matching placebo tablets for each of the interventions once daily for 7 days

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00618995 - A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED) | Biotech Hunter | Biotech Hunter